Recurrent pregnancy loss (RPL) is devastating and has an adverse psychosocial impact on women and on their families. Thrombotic events at the placenta resulting in adverse pregnancy outcome, is the common problem in hereditary thrombophilia. The M2/ANXA5 haplotype is one of the newly recognized hereditary thrombophilia RPL susceptibility gene, RPRGL3, OMIM entry 614391. An intervention of low-molecular-weight heparin (LMWH) anticoagulant treatment can benefit M2/ANXA5 RPL carriers for a possible healthy pregnancy outcome. This is a case report of a heterozygous M2 carrier couple (both parents) with a history of 4 consecutive miscarriages where Antiphospholipid Syndrome had been ruled out. They underwent a combination of aspirin and LMWH treatment and delivered a live healthy singleton baby. The newborn’s blood was collected and was also found to be an M2/ANXA5 carrier. Thus, anticoagulation treatment might well be a remedy for M2 carriers who experience recurrent miscarriage. However, the efficacy of this treatment needs to be addressed in a properly powered clinical trial in RPL couples found to carry this gene.